Cardiologists received a nice bump in pay in 2026 thanks to a one-time 2.5% conversion factor increase. That expires at the end of the year, however, and physicians will see their payments decrease as a result.

Treating asymptomatic patients with TAVR may cost more at first, but it appears to be a wise financial decision as time goes on.

iRhythm has agreed to acquire VitalConnect for approximately $237.5 million in cash and another $50 million in common stock.

The company's flagship technology was invented by Peter Spector, MD, a practicing electrophysiologist. It uses advanced electrodes to visualize details of AFib typically missed by other mapping systems.

The deal, first announced in April, includes an upfront payment of $20 million and up to an additional $25 million based on certain milestones.

Vexev, an Australian medtech company, wants to improve patient access to high-quality vascular imaging. The company has now raised a total of $19 million.

“We have colonoscopies, we have mammograms, but we have not had equivalents for most forms of heart disease,”  Pierre Elias, MD, Pathway Labs founder and CEO, explained.

A recent OIG report suggested vascular surgeons, interventional cardiologists and interventional radiologists may be performing medically unnecessary procedures in office-based labs. Now, some of the leading medical societies from those fields have provided additional context.